These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 7781270)

  • 21. Pemoline-induced Tourette's disorder: a case report.
    Bachman DS
    Am J Psychiatry; 1981 Aug; 138(8):1116-7. PubMed ID: 6942661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Attention deficit hyperactivity disorder in children].
    Bervoets L
    J Pharm Belg; 2002; 57(2):25-32. PubMed ID: 12053824
    [No Abstract]   [Full Text] [Related]  

  • 23. Blood levels and tolerance to stimulants in ADDH children.
    Swanson JM; Lerner M; Cantwell D
    Clin Neuropharmacol; 1986; 9 Suppl 4():523-5. PubMed ID: 3567959
    [No Abstract]   [Full Text] [Related]  

  • 24. Levofloxacin-induced acute fulminant hepatic failure in a patient with chronic hepatitis B infection.
    Coban S; Ceydilek B; Ekiz F; Erden E; Soykan I
    Ann Pharmacother; 2005 Oct; 39(10):1737-40. PubMed ID: 16105873
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prolonged P300 latency in attention deficit hyperactivity disorder predicts poor response to imipramine.
    Sangal JM; Sangal RB; Persky B
    Clin Electroencephalogr; 1996 Oct; 27(4):191-201. PubMed ID: 9465283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Compliance with FDA recommendations for pemoline.
    Sarkis EH
    J Am Acad Child Adolesc Psychiatry; 2003 Apr; 42(4):383; author reply 383. PubMed ID: 12649623
    [No Abstract]   [Full Text] [Related]  

  • 28. Pemoline (Cylert)-induced hepatotoxicity.
    Elitsur Y
    J Pediatr Gastroenterol Nutr; 1990 Jul; 11(1):143-4. PubMed ID: 2388127
    [No Abstract]   [Full Text] [Related]  

  • 29. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pemoline and lithium in a patient with attention deficit disorder.
    Brown RP; Ingber PS; Tross S
    J Clin Psychiatry; 1983 Apr; 44(4):146-8. PubMed ID: 6403515
    [No Abstract]   [Full Text] [Related]  

  • 31. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
    Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P
    Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Attention deficit hyperactivity disorder: pharmacological options that are not "Ritalin"].
    Shmueli D; Gross-Tsur V
    Harefuah; 2005 Aug; 144(8):572-6, 597. PubMed ID: 16146157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NTP Toxicology and Carcinogenesis Studies of Methylphenidate Hydrochloride (CAS No. 298-59-9) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1995 Jul; 439():1-299. PubMed ID: 12595924
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacotherapy of attention-deficit/hyperactivity disorder in adults.
    Wender PH
    J Clin Psychiatry; 1998; 59 Suppl 7():76-9. PubMed ID: 9680056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aplastic anemia after transplantation for non-A, non-B, non-C fulminant hepatic failure: case report and review of the literature.
    Itterbeek P; Vandenberghe P; Nevens F; Fevery J; Aerts R; Yap SH; Demuynck H; Fourneau I; Koshiba T; Emonds MP; Roskams T; Boogaerts M; Pirenne J
    Transpl Int; 2002 Mar; 15(2-3):117-23. PubMed ID: 11935168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pemoline, methylphenidate, and placebo in children with minimal brain dysfunction.
    Conners CK; Taylor E
    Arch Gen Psychiatry; 1980 Aug; 37(8):922-30. PubMed ID: 7406656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An n-of-1 trial service in clinical practice: testing the effectiveness of stimulants for attention-deficit/hyperactivity disorder.
    Nikles CJ; Mitchell GK; Del Mar CB; Clavarino A; McNairn N
    Pediatrics; 2006 Jun; 117(6):2040-6. PubMed ID: 16740846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pemoline and hepatotoxicity.
    McCurry L; Cronquist S
    Am J Psychiatry; 1997 May; 154(5):713-4. PubMed ID: 9137138
    [No Abstract]   [Full Text] [Related]  

  • 39. Pemoline pharmacokinetics and long term therapy in children with attention deficit disorder and hyperactivity.
    Collier CP; Soldin SJ; Swanson JM; MacLeod SM; Weinberg F; Rochefort JG
    Clin Pharmacokinet; 1985; 10(3):269-78. PubMed ID: 4017397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect on growth in pemoline-treated children with attention deficit disorder.
    Friedmann N; Thomas J; Carr R; Elders J; Ringdahl I; Roche A
    Am J Dis Child; 1981 Apr; 135(4):329-32. PubMed ID: 7211792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.